

|   |                                      |                               |
|---|--------------------------------------|-------------------------------|
| Form 1449*  | Atty. Docket No.: 295.022US1         | Serial No. Unknown 08/927,937 |
| INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br>(Use several sheets if necessary) | Applicants: David J. Grainger et al. |                               |
|   | Filing Date: Herewith 9/11/97        | Group: Unknown 08/927,937     |

1646

## U.S. PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date       | Name            | Class | Subclass | Filing Date If Appropriate |
|--------------------|-----------------|------------|-----------------|-------|----------|----------------------------|
| PM                 | 5,202,118       | 04/13/1993 | Gillis, et al.  | 424   | 85.2     | 05/06/91                   |
|                    | 5,212,073       | 05/18/1993 | Rollins, et al. | 435   | 69.5     | 05/12/89                   |
|                    | 5,401,651       | 03/28/1995 | Walz            | 435   | 240.2    | 10/16/91                   |
| ↓                  | 5,650,150       | 07/22/1997 | Gillies         | 424   | 134.1    | 07/27/94                   |

## FOREIGN PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date       | Country | Class | Subclass | Translation Yes   No |
|--------------------|-----------------|------------|---------|-------|----------|----------------------|
| PM                 | 90/07863        | 07/26/1990 | PCT     | C07K  | 7/10     |                      |
|                    | 92/20372        | 11/26/1992 | PCT     | A61K  | 37/66    |                      |
| ↓                  | 93/11159        | 06/10/1993 | PCT     | C07K  | 13/00    |                      |

## OTHER DOCUMENTS


(Including Author, Title, Date, Pertinent Pages, Etc.)

|    |  |
|----|--|
| PM | Arenzana-Seisdedos, F., et al., "HIV Blocked by Chemokine Antagonists", <u>Nature</u> , 383, 400, (Oct. 3, 1996)   |
| PM | Clark-Lewis, I., et al., "Structural Requirements for Interleukin-8 Function Identified by Design of Analogs and CXC Chemokine Hybrids", <u>J. Biol. Chem.</u> , 269, 16075-16081, (June 10, 1994)   |
| PM | Cocchi, F., et al., "Identification of RANTES, MIP-1 $\alpha$ , and MIP-1 $\beta$ as the Major HIV-Suppressive Factors Produced by CD8 $+$ T Cells", <u>Science</u> , 270, 1811-1815, (Dec. 15, 1995)  |
| PM | Jameson, B.A., et al., "A Rationally Designed CD4 Analogue Inhibits Experimental Allergic Encephalomyelitis", <u>Nature</u> , 368, 744-745 (Apr. 21, 1994)   |
| PM | Lusti-Narasimhan, M., et al., "A Molecular Switch of Chemokine Receptor Selectivity", <u>J. Biol. Chem.</u> , 271, 3148-3153, (Feb. 9, 1996)   |
| PM | Yahi, N., et al., "SPC3, a Synthetic Peptide Derived from the V3 Domain of Human Immunodeficiency Virus Type 1 (HIV-1) gp120, Inhibits HIV-1 Entry into CD4 $+$ and CD4 $-$ Cells by Two Distinct Mechanisms", <u>Natl. Acad. Sci. USA</u> , 92, 4867-4871, (May 1995) |
| PM | Zhang, Y., et al., "A Dominant Negative Inhibitor Indicates that Monocyte Chemoattractant Protein 1 Functions as a Dimer", <u>Mol. and Cell Biol.</u> , 15, 4851-4855, (Sept. 1995)  |
| PM | Zhang, Y., et al., "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis", <u>J. Biol. Chem.</u> , 269, 15918-15924 (1994)   |

|                                |                                   |
|--------------------------------|-----------------------------------|
| Examiner<br><i>Premra Menk</i> | Date Considered<br><i>3/26/99</i> |
|--------------------------------|-----------------------------------|

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 2 of 4

|   |                                      |                       |
|---|--------------------------------------|-----------------------|
| Form 1449*  | Atty. Docket No.: 295.022US1         | Serial No. 08/927,939 |
| INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br>(Use several sheets if necessary) | Applicants: David J. Grainger et al. |                       |
|   | Filing Date: September 11, 1997      | Group: 1646<br>1801   |

#### U. S. PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date       | Name                 | Class | Subclass | Filing Date If Appropriate |
|--------------------|-----------------|------------|----------------------|-------|----------|----------------------------|
| PM                 | 4,724,232       | 02/09/1988 | Rideout et al.       | 514   | 50       | 09/17/95                   |
|                    | 5,079,228       | 01/07/1992 | Cohen et al.         | 514   | 12       | 02/05/90                   |
|                    | 5,302,384       | 04/12/1994 | Gimbrone, Jr. et al. | 424   | 85.2     | 02/25/93                   |
|                    | 5,458,874       | 10/17/1995 | Pereira et al.       | 424   | 85.1     | 10/30/92                   |
|                    | 5,459,128       | 10/17/1995 | Rollins et al.       | 514   | 8        | 10/27/94                   |
|                    | 5,474,983       | 12/12/1995 | Kuna et al.          | 514   | 12       | 03/15/93                   |
|                    | 5,556,757       | 09/17/1996 | Alstyne et al.       | 435   | 7.2      | 06/07/95                   |
|                    | 5,571,713       | 11/05/1996 | Lyle et al.          | 435   | 240.2    | 05/27/94                   |
|                    | 5,578,714       | 11/26/1996 | Pogo et al.          | 536   | 23.5     | 10/21/93                   |
|                    | 5,605,671       | 02/25/1997 | Lyle et al.          | 424   | 1.41     | 04/29/94                   |
|                    | 5,627,156       | 05/06/1997 | Talmadge             | 514   | 13       | 09/23/94                   |
|                    | 5,646,117       | 07/08/1997 | Matsushima et al.    | 514   | 12       | 03/25/95                   |
|                    | 5,661,132       | 08/26/1997 | Eriksson et al.      | 514   | 44       | 11/22/94                   |
|                    | 5,705,360       | 01/06/1998 | Rollins et al.       | 435   | 69.1     | 07/16/96                   |
|                    | 5,707,814       | 01/13/1998 | Levy et al.          | 435   | 7.1      | 03/05/96                   |
| ↓                  | 5,707,815       | 01/13/1998 | Charo et al.         | 435   | 7.2      | 05/25/95                   |

#### FOREIGN PATENT DOCUMENTS

| **Examiner Initial | Document Number | Date       | Country | Class | Subclass | Translation Yes   No |
|--------------------|-----------------|------------|---------|-------|----------|----------------------|
| PM                 | 9-255570 A      | 03/21/1996 | Japan   | A61K  | 031/35   | With Abstract        |
|                    | 91/08483        | 06/13/1991 | PCT     | G01N  | 33/53    |                      |
|                    | 92/04372        | 03/19/1992 | PCT     | C07K  | 7/00     |                      |
|                    | 96/22371        | 07/25/1996 | PCT     | C12N  | 15/12    |                      |
|                    | 97/12615        | 04/10/1997 | PCT     | A61K  | 31/425   |                      |
|                    | 97/21812        | 06/19/1997 | PCT     | C12N  | 15/19    |                      |
|                    | 97/22698        | 06/26/1997 | PCT     | C12N  | 15/12    |                      |
|                    | 97/25427        | 07/17/1997 | PCT     | C12N  | 15/19    |                      |
|                    | 97/29192        | 08/14/1997 | PCT     | C12N  | 15/19    |                      |
|                    | 97/31098        | 08/28/1997 | PCT     | C12N  | 1/20     |                      |
| ↓                  | 97/32019        | 09/04/1997 | PCT     | C12N  | 15/12    |                      |

RECEIVED  
SEP 22 1999  
GROUP 1801C

#### OTHER DOCUMENTS


(Including Author, Title, Date, Pertinent Pages, Etc.)

|                    |   |
|--------------------|---|
| **Examiner Initial |   |
| PM                 | "Blocking CCR5 Stops M-tropic HIV Infection", <u>Biotechnology News</u> , 17, 3 (1997)  |
| PM                 | Buckley, C.D., "Treatment of Rheumatoid Arthritis", <u>BMJ</u> , 315, 236-238 (July 26, 1997)   |
| PM                 | Clark-Lewis, I., et al., "Platelet Factor 4 Binds to Interleukin 8 Receptors and Activates Neutrophils When its N Terminus is Modified with Glu-Leu-Arg", <u>Proceedings of the National Academy of Sciences, USA</u> , 90, 3574-3577, (1993) |

Examiner Premal Mehta | Date Considered | 3/29/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 3 of 4

|   |                                      |                       |
|---|--------------------------------------|-----------------------|
| Form 1449*  | Att'y Docket No.: 295.022US1         | Serial No. 08/927,939 |
| INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br>(Use several sheets if necessary) | Applicants: David J. Grainger et al. |                       |
|   | Filing Date: September 11, 1997      | Group: 1801 1646      |

**RECEIVED**

SEP 6 1998

\*\*Examiner Initial

GROUP 1800

#### OTHER DOCUMENTS


(Including Author, Title, Date, Pertinent Pages, Etc.)

- PM Clark-Lewis, I., et al., "Structure-Activity Relationships of Interleukin-8 Determined Using Chemically Synthesized Analogs", The Journal of Biological Chemistry, 266, 23128-23134, (1991)
- Drazen, J.M., et al., "Treatment of Chronic Stable Asthma with Drugs Active on the 5-Lipoxygenase Pathway", Int. Arch. Allergy Immunol., 107, 319-320 (1995)
- Gong, J.-H., et al., "An Antagonist of Monocyte Chemoattractant Protein 1 (MCP-1) Inhibits Arthritis in the MRL-lpr Mouse Model", J. Exp. Med., 186, 131-137 (July 7, 1997)
- Grossman, J., et al., "Results of the First U.S. Double-Blind, Placebo-Controlled, Multicenter Clinical Study in Asthma with Pranlukast, a Novel Leukotriene Receptor Antagonist", Journal of Asthma, 34, 321-328 (1997)
- Hauser, S.L., "Therapeutic Strategies for Multiple Sclerosis", J. Neurochem., 69, Suppl., Abstract A, p. S219 (1997)
- Hendeles, L., et al., "Zafirlukast for Chronic Asthma: Convenient and Generally Safe, But Is It Effective?", The Annals of Pharmacotherapy, 31, 1084-1086 (Sep. 1997)
- Hilliquin, P., et al., "Treatment of Rheumatoid Arthritis with Platelet Activating Factor Antagonist BN 50730", J. Rheumatol., 22, 1651-1654 (1995)
- Hogan, S.P., et al., "Cytokines as Targets for the Inhibition of Eosinophilic Inflammation", Pharmacol. Ther., 74, 259-283 (1997)
- Hunter, M.G., et al., "BB-10010: An Active Variant of Human Macrophage Inflammatory Protein-1 $\alpha$  with Improved Pharmaceutical Properties" Blood, 86, 4400-4408 (Dec. 15, 1995)
- Ishikawa, J., et al., "Effect of YM934, a Novel Potassium-Channel Opener, in Various Experimental Asthma Models in Guinea-pigs", J. Pharm. Pharmacol., 48, 1034-1040 (1996)
- Israel, E., et al., "Effect of Treatment With Zileuton, a 5-Lipoxygenase Inhibitor, in Patients With Asthma", JAMA, 275, 931-936 (Mar. 27, 1996)
- Katz, M.D., et al., "Octreotide, a New Somatostatin Analogue", Clinical Pharmacy, 8, 255-273 (Apr. 1989)

Examiner Premal Mehta | Date Considered 3/29/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 1 of 5

Form 1449\*

Atty. Docket No.: 295.022US1

Serial No. 08/927,939

INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT  
(Use several sheets if necessary)

Applicants: David J. Grainger et al.

Filing Date: September 11, 1997

Group: 1804646

**RECEIVED**

\*\*Examiner  
Initial

SEP 21 1998

OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

GROUP 1800


|    |  |
|----|--|
| PM | Klareskog, L., et al., "Immunopathogenesis and Immunotherapy in Rheumatoid Arthritis: an Area in Transition", <u>Journal of Internal Medicine</u> , 238, 191-206 (1995)  |
|    | Kledel, T.N., et al., "A Broad-Spectrum Chemokine Antagonist Encoded by Kaposi's Sarcoma-Associated Herpesvirus", <u>Science</u> , 277, 1656-1659 (Sep. 12, 1997)  |
|    | Leong, S.R., et al., "Complete Mutagenesis of the Extracellular Domain of Interleukin-8 (IL-8) Type A Receptor Identifies Charged Residues Mediating IL-8 Binding and Signal Transduction", <u>Journal of Biological Chemistry</u> , 19343-19348, (1994) |
|    | Lowe, P.M., et al., "The Endothelium in Psoriasis", <u>British Journal of Dermatology</u> , 132, 497-505 (1995)  |
|    | Malkowski, M.G., et al., "The Crystal Structure of Recombinant Human Neutrophil-Activating Peptide-2 (M6L) at 1.9-Å Resolution", <u>The Journal of Biological Chemistry</u> , 270, 7077-7087 (Mar. 31, 1995)   |
|    | Miller, E.J., et al., "A Synthetic Peptide which Specifically Inhibits Heat-Treated Interleukin-8 Binding and Chemotaxis for Neutrophils", <u>Agents Actions</u> , 40, 200-208 (1993)  |
|    | Mölling, K., "Naked DNA for Vaccine or Therapy", <u>J. Mol. Med.</u> , 75, 242-246 (1997)  |
|    | Moser, B., et al., "Interleukin-8 Antagonists Generated by N-Terminal Modification", <u>The Journal of Biological Chemistry</u> , 268, 7125-7128 (1993)  |
|    | Myers, L.K., et al., "Collagen-Induced Arthritis, an Animal Model of Autoimmunity", <u>Life Sciences</u> , 61, 1861-1878 (1997)  |
|    | Plater-Zyberk, C., et al., "Effect of a CC Chemokine Receptor Antagonist on Collagen Induced Arthritis in DBA/1 Mice", <u>Immunology Letters</u> , 57, 117-120 (1997)  |
|    | Reiss, T.F., et al., "Effects of Montelukast (MK-0476), a New Potent Cysteinyl Leukotriene (LTD <sub>4</sub> ) Receptor Antagonist, in Patients with Chronic Asthma", <u>J. Allergy Clin. Immunol.</u> , 98, 528-534 (Sep. 1996)                         |
|    | Simmons, G., et al., "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist", <u>Science</u> , 276, 276-279 (Apr. 11, 1997)   |

Examiner Premra Meny

Date Considered  
3/29/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Sheet 5 of 5

|   |                                      |                       |
|---|--------------------------------------|-----------------------|
| Form 1449*  | Atty. Docket No.: 295.022US1         | Serial No. 08/927,939 |
| INFORMATION DISCLOSURE STATEMENT<br>BY APPLICANT<br>(Use several sheets if necessary) | Applicants: David J. Grainger et al. |                       |
|   | Filing Date: September 11, 1997      | Group: 1801 1646      |

**RECEIVED**

**SEP 6 1999**

**GROUP 1800**

**OTHER DOCUMENTS**

(Including Author, Title, Date, Pertinent Pages, Etc.)

\*\*Examiner Initial

|    |   |
|----|---|
| PM | Smith, L.J., et al., "Inhibition of Leukotriene D <sub>4</sub> -Induced Bronchoconstriction in Subjects With Asthma: A Concentration-Effect Study of ICI 204,219", <u>Clin. Pharmacol. Ther.</u> , 54, 430-436 (1993)                             |
|    | Spector, S.L., "Leukotriene Activity Modulation in Asthma", <u>Drugs</u> , 54, 369-384 (Sep. 1997)  |
|    | Spector, S.L., et al., "Effects of 6 Weeks of Therapy with Oral Doses of ICI 204,219, a Leukotriene D <sub>4</sub> Receptor Antagonist, in Subjects with Bronchial Asthma", <u>Am. J. Respir. Crit. Care Med.</u> , 150, 618-623 (1994)           |
|    | Suissa, S., et al., "Effectiveness of the Leukotriene Receptor Antagonist Zafirlukast for Mild-to-Moderate Asthma", <u>Ann. Intern. Med.</u> , 126, 177-183 (1997)  |
|    | Tamura, G., et al., "Effect of a Potent Platelet-Activating Factor Antagonist, WEB-2086, on Asthma", In: <u>Platelet-Activating Factor and Related Lipid Mediators</u> , 2, Nigam, et al., (eds.), Plenum Press, New York, 371-380 (1996)         |
|    | Valente, A.J., et al., "Characterization of Monocyte Chemotactic Protein-1 Binding to Human Monocytes", <u>Biochemical and Biophysical Research Communications</u> , 176, 309-314 (Apr. 15, 1991)   |
|    | Weber, M., et al., "Deletion of the NH <sub>2</sub> -Terminal Residue Converts Monocyte Chemotactic Protein 1 from an Activator of Basophil Mediator Release to an Eosinophil Chemoattractant", <u>J. Exp. Med.</u> , 183, 681-685 (Feb. 1996)    |
|    | Wells, T.N.C., et al., "The Molecular Basis of Selectivity Between CC and CXC Chemokines: The Possibility of Chemokine Antagonists as Anti-Inflammatory Agents", <u>Annals of the New York Academy of Sciences</u> , 796, 245-257 (Oct. 31, 1996) |
|    | Wells, T.N.C., et al., "The Molecular Basis of the Chemokine/Chemokine Receptor Interaction -- Scope for Design of Chemokine Antagonists", <u>Methods: A Companion to Methods in Enzymology</u> , 10, 126-134 (1996)                              |
| ✓  | Wooley, P.H., et al., "Influence of a Recombinant Human Soluble Tumor Necrosis Factor Receptor FC Fusion Protein on Type II Collagen-Induced Arthritis in Mice", <u>The Journal of Immunology</u> , 151, 6602-6607 (Dec. 1, 1993)                 |

Examiner Penna Menk | Date Considered 3/29/99

\*Substitute Disclosure Statement Form (PTO-1449)

\*\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.